Alkem Laboratories announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of epilepsy in India.
Brivasure, Alkem’s anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg Rs. 79.50/strip, Brivasure 50mg 148.50/strip, Brivasure 75mg 230/strip, Brivasure 100mg 295/strip, post-patent expiry of innovator product, of Brivaracetam as on February 21, 2021. The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial-onset seizure with or without secondary generalisation. The drug has exhibited a faster onset of action, efficacy with a favourable safety profile.
Kaushal, President, Chronic Business said, “With the launch of Brivasure, we aim to make the treatment of epilepsy easily accessible to the patients at affordable pricing. We believe that healthcare is not just about curing people but enriching their lives. The introduction of Brivasure is a testimony to our commitment to improve the quality of life and treatment compliance of epilepsy patients in India.”
Dr Akhilesh Sharma, President and CMO added, “With the introduction of brivaracetam by Alkem, we are optimistic about making steady progress and revolutionising Epilepsy treatment in India as well as globally. Levetiracetam has been considered a broad-spectrum antiepileptic drug in India but after clinical usage for over a decade we have learnt that it has got its own disadvantages and is associated with certain behavioural side effects. Brivaracetam seems to be filling up this gap with its promising efficacy which was observed even in those patients who had previously discontinued Levetiracetam due to side effects, benign side effects and simpler dosing regimen making it more convenient and cost-effective proposition for the patients.”